Table 2 Correlation between TIMP1 expression and clinicopathological characteristics
|  | Total (n = 94) | TIMP1 protein expression | P-value | |
|---|---|---|---|---|
Negative (n = 44) | Positive (n = 50) | |||
Age | ||||
  < 65 | 43 (45.7 %) | 21 (47.7 %) | 22 (44.0 %) | 0.717 |
  ≥ 65 | 51 (54.3 %) | 23 (52.3 %) | 28 (56.0 %) |  |
Gender | ||||
 Male | 47 (50.0 %) | 23 (52.3 %) | 24 (48.0 %) | 0.679 |
 Female | 47 (50.0 %) | 21 (47.7 %) | 26 (52.0 %) |  |
Tumor location | ||||
 Right | 25 (26.6 %) | 12 (27.3 %) | 13 (26.0 %) | 0.423 |
 Transverse | 9 (9.6 %) | 5 (11.4 %) | 4 (8.0 %) |  |
 Left | 10 (10.6 %) | 6 (13.6 %) | 4 (8.0 %) |  |
 Others | 50 (53.2 %) | 21 (47.7 %) | 29 (58.0 %) |  |
T stage | ||||
 T1 + T2 | 23 (24.5 %) | 10 (22.7 %) | 13 (26.0 %) | 0.713 |
 T3 + T4 | 71 (75.5 %) | 34 (77.3 %) | 37 (74.0 %) |  |
N stage | ||||
 N0 | 51 (54.3 %) | 29 (65.9 %) | 22 (44.0 %) | 0.033* |
 N1 + N2 | 43 (45.7 %) | 15 (34.1 %) | 28 (56.0 %) |  |
M stage | ||||
 M0 | 80 (85.1 %) | 41 (93.2 %) | 39 (78.0 %) | 0.039* |
 M1 | 14 (14.9 %) | 3 (6.8 %) | 11 (22.0 %) |  |
Vascular invasion | ||||
 No | 85 (90.4 %) | 43 (97.7 %) | 42 (84.0 %) | 0.024* |
 Yes | 9 (9.6 %) | 1 (2.3 %) | 8 (16.0 %) |  |
Differentiation | ||||
 Well | 27 (28.8 %) | 9 (20.4 %) | 18 (36.0 %) | 0.186 |
 Moderate | 49 (52.1 %) | 27 (61.4 %) | 22 (44.0 %) |  |
 Poor | 18 (19.1 %) | 8 (18.2 %) | 10 (20.0 %) |  |
AJCC stage | ||||
 I + II | 42 (44.7 %) | 25 (56.8 %) | 17 (34.0 %) | 0.026* |
 III + IV | 52 (55.3 %) | 19 (43.2 %) | 33 (66.0 %) |  |